Form 4: Bionano Genomics CEO Reports Routine Stock Withholding for Tax Obligations
Insider Transaction Report
Bionano Genomics' President and CEO, R. Erik Holmlin, reported the withholding of 75 shares of common stock valued at $3.69 per share on June 3, 2025, to cover tax obligations related to a vested RSU award.
Summary
- R. Erik Holmlin, President and CEO, and a Director of Bionano Genomics, Inc. (BNGO), filed a Form 4 detailing a change in beneficial ownership.
- On June 3, 2025, 75 shares of Bionano Genomics common stock were disposed of (withheld) by the Issuer.
- The shares were withheld at a price of $3.69 per share to satisfy the reporting person's tax withholding obligations.
- This transaction was in connection with the settlement of a Restricted Stock Unit (RSU) award that vested on June 3, 2025, originally granted on June 3, 2024.
- Following this transaction, R. Erik Holmlin beneficially owns 1,708 shares directly and 8 shares indirectly through a Traditional IRA, totaling 1,716 shares.
Sentiment
Score: 5
Explanation: The transaction is a routine tax withholding related to executive compensation, which is a neutral event and does not indicate positive or negative sentiment about the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of RSU award grant. |
| 06/03/2025 | Date RSU award vested and shares were withheld for tax obligations. |
Keywords
Bionano Genomics, BNGO, R. Erik Holmlin, Form 4, Insider Transaction, Stock Withholding, RSU, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.